Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.29

Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol (2009) 0.97

Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol (2012) 0.97

Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol (2011) 0.96

Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag (2009) 0.90

Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin Res Cardiol (2010) 0.88

Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol (2011) 0.86

Clopidogrel in acute coronary syndrome: when, how much, how long? Z Kardiol (2005) 0.86

Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J (2008) 0.84

Humanized mouse model of thrombosis is predictive of the clinical efficacy of antiplatelet agents. Circulation (2011) 0.83

Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura. Heart (2005) 0.83

Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clin Res Cardiol (2007) 0.83

Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. Heart Vessels (2006) 0.82

Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction. Heart (2004) 0.82

Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res (2013) 0.81

Antiplatelet treatment for coronary heart disease. Heart (2007) 0.80

Safety and Efficacy of Acute Clopidogrel Load in Patients with Moderate and Severe Ischemic Strokes. Stroke Res Treat (2016) 0.79

Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. Heart Vessels (2011) 0.78

Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism. CMAJ (2006) 0.75

Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention. Heart (2005) 0.75

Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.75

Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis. PLoS One (2011) 0.75

Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. Heart (2005) 0.75

Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. West J Emerg Med (2009) 0.75

Effect of 450-mg loading dose of clopidogrel on platelet function in Japanese patients undergoing coronary stent placement. Heart Vessels (2010) 0.75

Sarpogrelate Based Triple Antiplatelet Therapy Improved Left Ventricular Systolic Function in Acute Myocardial Infarction: Retrospective Study. Yonsei Med J (2017) 0.75

Perceptions by family members of the dying experience of older and seriously ill patients. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med (1997) 6.55

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med (1996) 6.05

Epidemiology, aetiology, and prognosis of heart failure. Heart (2000) 4.42

Dying from heart disease. J R Coll Physicians Lond (1997) 2.87

Knowledge and communication difficulties for patients with chronic heart failure: qualitative study. BMJ (2000) 2.47

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation (2000) 2.28

Communication and choice in dying from heart disease. J R Soc Med (1997) 1.70

Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery. Heart (2000) 1.41

Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol (1999) 1.38

A comparison of four quality of life instruments in cardiac patients: SF-36, QLI, QLMI, and SEIQoL. Heart (2000) 1.28

Thyroid disease and the heart. Heart (2000) 1.18

Radiofrequency catheter ablation of ventricular tachycardia. Heart (2000) 1.18

Pharmacogenetics and the treatment of cardiovascular disease. Heart (2000) 1.00

When should ACE inhibitors or warfarin be discontinued after myocardial infarction? Heart (2000) 0.95

Heart disease in the elderly. Heart (2000) 0.90

Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost (1998) 0.89

Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. Infect Immun (1987) 3.87

Cloning of the complete human cytomegalovirus genome in cosmids. Gene (1982) 3.55

On the origin and direction of replication of the Escherichia coli K12 chromosome. J Mol Biol (1968) 3.46

Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet (1999) 3.38

Identification of thermolabile Escherichia coli proteins: prevention and reversion of aggregation by DnaK and ClpB. EMBO J (1999) 3.20

Effective protection against Listeria monocytogenes and delayed-type hypersensitivity to listerial antigens depend on cooperation between specific L3T4+ and Lyt 2+ T cells. Infect Immun (1985) 2.70

A cycle of binding and release of the DnaK, DnaJ and GrpE chaperones regulates activity of the Escherichia coli heat shock transcription factor sigma32. EMBO J (1996) 2.55

Multistep mechanism of substrate binding determines chaperone activity of Hsp70. Nat Struct Biol (2000) 2.37

Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science (1996) 2.35

Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel. Parasitology (2001) 2.34

Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation (2001) 2.34

Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation (1996) 2.20

Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency. Clin Chim Acta (1983) 2.17

Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res (1984) 2.17

Herpesvirus saimiri DNA in a lymphoid cell line established by in vitro transformation. J Virol (1984) 2.09

Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation (1997) 2.06

Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J (2001) 2.06

[Efficacy of epidural steroid injections for chronic lumbar pain syndromes without neurological deficits. A randomized, double blind study as part of a multimodal treatment concept]. Schmerz (2015) 1.99

Activated platelets induce monocyte chemotactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation (1998) 1.95

A qualitative study of physicians' own wellness-promotion practices. West J Med (2001) 1.88

Regulatory region C of the E. coli heat shock transcription factor, sigma32, constitutes a DnaK binding site and is conserved among eubacteria. J Mol Biol (1996) 1.85

Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol (1997) 1.84

Monitoring of cellular behaviour by impedance measurements on interdigitated electrode structures. Biosens Bioelectron (1997) 1.83

Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation (1996) 1.75

Phenotypic variation in biotinidase deficiency. J Pediatr (1983) 1.74

Comparative West Nile virus detection in organs of naturally infected American Crows (Corvus brachyrhynchos). Emerg Infect Dis (2001) 1.73

Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol (1998) 1.73

Mutational hotspot in the human biotinidase gene causes profound biotinidase deficiency. Nat Genet (1995) 1.67

Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation (1995) 1.66

Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv (2000) 1.65

Biotinylation of histones by human serum biotinidase: assessment of biotinyl-transferase activity in sera from normal individuals and children with biotinidase deficiency. Biochem Mol Med (1995) 1.64

Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation (1998) 1.63

Vessel size and long-term outcome after coronary stent placement. Circulation (1998) 1.61

Physical activity is independently related to aerobic capacity in cystic fibrosis. Eur Respir J (2006) 1.61

Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience (2000) 1.61

Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation. Circulation (2001) 1.61

Tuning of chaperone activity of Hsp70 proteins by modulation of nucleotide exchange. Nat Struct Biol (2001) 1.61

Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med (2008) 1.60

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg (2012) 1.60

Associations of peak shifts in age--prevalence for human malarias with bednet coverage. Trans R Soc Trop Med Hyg (2001) 1.58

PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. J Am Coll Cardiol (2000) 1.56

Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation (2000) 1.56

Operator volume and outcome of patients undergoing coronary stent placement. J Am Coll Cardiol (1998) 1.56

Dissociation between coronary sinus and left atrial conduction in patients with atrial fibrillation and flutter. J Cardiovasc Electrophysiol (2001) 1.56

The characteristics and genetic map location of a temperature sensitive DNA mutant of E. coli K12. Genetics (1972) 1.55

Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers. J Am Coll Cardiol (2001) 1.55

Immunoglobulin determinants on the lymphocytes of normal rabbits. 3. As4 and As6 determinants on individual lymphocytes and the concept of allelic exclusion. Immunology (1971) 1.54

A comparison of treatment of atrial fibrillation with low-energy intracardiac cardioversion and conventional external cardioversion. Eur Heart J (1997) 1.53

Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet (2001) 1.53

Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost (2010) 1.52

Distribution of binding sequences for the mitochondrial import receptors Tom20, Tom22, and Tom70 in a presequence-carrying preprotein and a non-cleavable preprotein. J Biol Chem (1999) 1.50

Comparison of angiography and intravascular ultrasound for the assessment of lumen size after coronary stent placement: impact of dilation pressures. Cathet Cardiovasc Diagn (1997) 1.49

Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation (1997) 1.47

A screening method for biotinidase deficiency in newborns. Clin Chem (1984) 1.46

Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol (1990) 1.45

Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors In vivo by ultrasound-guided injection or transcoronary delivery. Circulation (2000) 1.45

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. J Clin Oncol (2001) 1.45

Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. Thromb Haemost (2012) 1.45

Adenosine inhibits norepinephrine release in the postischemic rat heart: the mechanism of neuronal stunning. Cardiovasc Res (2001) 1.45

Binding specificity of Escherichia coli trigger factor. Proc Natl Acad Sci U S A (2001) 1.45

The presence of Herpesvirus Saimiri genomes in virus-transformed cells. Int J Cancer (1977) 1.43

Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel. J Thromb Haemost (2006) 1.43

A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med (2004) 1.43

Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart (2007) 1.43

Impact of low copy repeats on the generation of balanced and unbalanced chromosomal aberrations in mental retardation. Cytogenet Genome Res (2006) 1.42

Gene transfer of heterologous G protein-coupled receptors to cardiomyocytes: differential effects on contractility. Circ Res (2001) 1.42

Structural transitions of deoxyribonucleic acid in aqueous electrolyte solutions. II. The role of hydration. Biochemistry (1975) 1.39

G protein beta3 subunit polymorphism and risk of thrombosis and restenosis following coronary stent placement. Atherosclerosis (2000) 1.39

Ligament length patterns, strength, and rotational axes of the knee joint. Clin Orthop Relat Res (1976) 1.39

Some Considerations of Vertigo based on Experience. Proc R Soc Med (1928) 1.39

Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol (1996) 1.38

Distribution of angiographic measures of restenosis after drug-eluting stent implantation. Heart (2009) 1.38

Early recovery of coronary flow reserve after stent implantation as assessed by positron emission tomography. J Am Coll Cardiol (1999) 1.38

Release of endogenous catecholamines in the ischemic myocardium of the rat. Part A: Locally mediated release. Circ Res (1984) 1.38

Calendar life span versus budding life span of Saccharomyces cerevisiae. Mech Ageing Dev (1980) 1.36

Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis (2001) 1.36

Haemoparasites of equines: impact on international trade of horses. Rev Sci Tech (1990) 1.31

Parental age and the life-span of zygotes of Saccharomyces cerevisiae. Antonie Van Leeuwenhoek (1985) 1.31

Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun (2001) 1.28

Molecular basis for interactions of the DnaK chaperone with substrates. Biol Chem (2001) 1.28

Biotinidase deficiency: initial clinical features and rapid diagnosis. Ann Neurol (1985) 1.26

On the origin and direction of replication of the E. coli chromosome. Cold Spring Harb Symp Quant Biol (1968) 1.26

Expression and kinetics of cytokines determined by intracellular staining using flow cytometry. J Immunol Methods (1999) 1.25

Exacerbation of experimental murine cutaneous leishmaniasis with CD4+ Leishmania major-specific T cell lines or clones which secrete interferon-gamma and mediate parasite-specific delayed-type hypersensitivity. Eur J Immunol (1991) 1.25

Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med (1992) 1.25

Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat (2001) 1.25

Biochemical differences between mutant propionyl-CoA carboxylases from two complementation groups. Am J Hum Genet (1978) 1.25

Influence of lesion length on restenosis after coronary stent placement. Am J Cardiol (1999) 1.25

Clinical heterogeneity in 80 home-reared children with cri du chat syndrome. J Pediatr (1983) 1.24

Restenosis after coronary placement of various stent types. Am J Cardiol (2001) 1.24